OA
EN
中文站 English
CN

Team Overview

With the notion of science above everything else, a strong tumor research team has been formed, combined with the academic background and interests of the scientists, and concentrated on tackling key tumor science and clinical core issues.
Home > Research Team > Team Overview

Changzheng Lu

Junior Principal Investigator

Changzheng.lu@szbl.ac.cn

Research Areas

Lu lab focuses on the mechanisms of infiltration, survival and exhaustion of T cells in tumor microenvironment, aiming to :

  • Develop pharmacological intervention to enhance anti-cancer immunotherapies;
  • Design novel tumor vaccines.





Honors

  • EACR Top 10 Cancer Research Publications in 2020
  • Merit Student of 2013/2014 and 2009/2010 school years in the Institute of Biophysics, Chinese Academy of Sciences
  • Excellent Student Cadre of 2009/2010 school year in Graduate University of Chinese Academy of Sciences

Pictorial View

  • 图.png

Timeline

  • 2022 – Present
    Shenzhen Bay Laboratory    Junior Principal Investigator
  • 2016 – 2022
    UT Southwestern Medical Center   Postdoc
  • 2009 – 2016
    Institute of Biophysics, CAS   PhD
  • 2005 – 2009
    Jiangnan University   Bachelor

Highlights

Dr. Lu started tumor immunology research in his PhD program when he took a collaborated project of developing innovative immunotherapies with Drs Yongjun Liu and Lixin Li from Seven & Eight Biopharma. Currently, the project has entered phase II clinical trial in US. During his postdoc training, one of Dr Lu’s work has been published as two research articles back-on-back in Cancer Cell, which discovers the mechanisms of responsiveness and non-responsiveness in anti-PD1 therapy against dMMR tumor and reveals the key role of tumor cells-intrinsic cGAS-STING pathway in the tumor-infiltrating of T cells. This work is highly evaluated by the scientific community, especially by Professors Andrés Cervantes (president of ESMO) and Alberto Bardelli ( president of EACR), and elected as “EACR TOP 10 Cancer Research Publications” in 2020.

Selected Publications

Lu, C., Guan, J., Lu, S., Jin, Q., Rousseau, B., Lu, T., ... & Fu, Y. X. (2021). DNA sensing in mismatch repair-deficient tumor cells is essential for anti-tumor immunity. Cancer Cell, 39(1), 96-108.

This paper is previewed by Cancer Cell (https://www.cell.com/cancer-cell/fulltext/S1535-6108(20)30664-4); Highlighted by Science Signaling (https://stke.sciencemag.org/content/14/666/eabg5661.full); A highly cited paper by Web of Science.

Guan, J.#, Lu, C.#, Jin, Q., Lu, H., Chen, X., Tian, L., ... & Li, G. M. (2021). MLH1 deficiency-triggered DNA hyperexcision by exonuclease 1 activates the cGAS-STING pathway. Cancer Cell, 39(1), 109-121. A highly cited paper by Web of Science.

Zhang, A., Ren, Z., Tseng, K. F., Liu, X., Li, H., Lu, C., ... & Fu, Y. X. (2021). Dual targeting of CTLA-4 and CD47 on Treg cells promotes immunity against solid tumors. Science Translational Medicine, 13(605), eabg8693.

Suresh, S., Chen, B., Zhu, J., Golden, R. J., Lu, C., Evers, B. M., ... & O’Donnell, K. A. (2020). eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer. Nature Cancer, 1(5), 533-545.

Li, H. D., Lu, C., Zhang, H., Hu, Q., Zhang, J., Cuevas, I. C., ... & Castrillon, D. H. (2020). A PoleP286R mouse model of endometrial cancer recapitulates high mutational burden and immunotherapy response. JCI insight, 5(14).